In a significant regulatory move, the UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Novo Nordisk’s (NYSE:NVO) Wegovy to help prevent major cardiovascular events, including heart attacks and strokes.
The guidance applies to adults who are living with obesity or who are overweight, and marks the first time a GLP-1 therapy has been formally endorsed for reducing cardiovascular risk, rather than being limited to treating diabetes or supporting weight loss.
Novo Nordisk said on Wednesday that the 2.4 mg dose of Wegovy will now be made available through the UK’s National Health Service (NHS).
The company added that the treatment is expected to be incorporated into existing cardiovascular care pathways, expanding its role in the management of heart-related health risks.